ADHD Drug Warnings In New Highlights Section Replaces Need For Black Box
Executive Summary
The ability to highlight warnings under FDA's new labeling rule may obviate the need for a "black box" warning against risks associated with attention deficit/hyperactivity disorder drugs, FDA's Pediatric Advisory Committee suggested March 22
You may also be interested in...
ADHD Drug MedGuides Show FDA’s Focus On Consumer Risk Communications
FDA's requirement that manufacturers of attention deficit/hyperactivity drugs develop patient medication guides illustrates the growing importance to the agency of communicating risks to the public
ADHD Drug MedGuides Show FDA’s Focus On Consumer Risk Communications
FDA's requirement that manufacturers of attention deficit/hyperactivity drugs develop patient medication guides illustrates the growing importance to the agency of communicating risks to the public
Shire Daytrana ADHD Patch To Launch In Early July With Some Class Labeling
Shire and manufacturing partner Noven expect an early July launch for Daytrana, the first transdermal patch for the treatment of attention deficit/hyperactivity disorder to receive FDA approval